Biocon rises as its arm secures exclusive global rights for Hulio
Biocon is currently trading at Rs. 401.40, up by 2.35 points or 0.59% from its previous closing of Rs. 399.05 on the BSE.
The scrip opened at Rs. 400.10 and has touched a high and low of Rs. 403.70 and Rs. 398.85 respectively. So far 78525 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 403.70 and Rs. 383.90 respectively. The current market cap of the company is Rs. 53665.72 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively.
Biocon’s subsidiary and a fully integrated global biosimilars company -- Biocon Biologics has secured full and exclusive global rights for Hulio (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics Co. (FKB). Under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights. Under the terms of this agreement, FKB will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.
Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO. Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio, which underscores the company’s strategic focus on expanding access to biologics for immune-mediated diseases worldwide.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
